ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1646

Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution

Mamoun Elnagar1, Yasser Radwan 1, Mohamed Elwazir 2, Reto Kurmann 2, Rekha Mankad 1, Thomas Osborn 1, Ashima Makol 1, Leroy Griffing 3, Cynthia Crowson 2 and Alicia Hinze 1, 1Mayo Clinic Minnesota, Rochester, MN, 2Mayo Clinic Minnesota, Rochester, 3Mayo Clinic Arizona, Scottsdale

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Scleroderma, systemic sclerosis and heart disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) associated heart involvement remains ill-defined, with non-ischemic systolic heart failure, conduction defects, and arrhythmias often included in the definition in clinical studies. Valvular heart disease (VHD) in SSc has not been well studied. In this referral-based single-institution cohort, we evaluate the incidence rate (IR) and prevalence of VHD in SSc.

Methods: In this retrospective cohort study, medical records of 506 cases with SSc seen between 1/1/2000 and 11/10/2018, with at least two echocardiograms in the health care system, were manually reviewed. All cases included fulfilled ACR/EULAR 2013 classification criteria for SSc or 3/5 CREST criteria, and had a baseline echocardiogram within five years of diagnosis. Mild, moderate, and severe VHD was clinically defined at time of echocardiogram. IR of VHD, per 100 person-years, and prevalence of VHD were determined. Cox models were used to examine associations between incident VHD and SSc characteristics as well as cardiovascular disease (CVD) risk factors, adjusting for age and sex.

Results: Demographics, SSc characteristics, and baseline CVD risk factors are reported in table 1. Mitral regurgitation (MR) was most common, with 20% of cases having at least mild MR on baseline echocardiogram (table 2). The prevalence of at least mild aortic regurgitation (AR) or aortic stenosis (AS) was 7% and 1%, respectively (table 2). The highest IR (IR) (per 100 person-years) was 6.36 (95% CI 5.24 – 7.59) for mild MR, followed by 1.80 (95% CI 1.31 – 2.36) for mild AR and 1.25 (95% CI 0.87 – 1.70) for mild AS (table 2). Development of severe VHD was only observed for AS, with an IR of 0.28 (95% CI 0.12 – 0.51). On age- and sex-adjusted hazard models examining baseline SSc and CVD risk factors for incident VHD, age remained a significant risk factor for all VHD types (table 3). Coronary artery disease (CAD) was associated with incidence of at least mild MR (HR 2.20, 95% CI 1.04 – 4.65) (table 3). Anti-Scl70 antibody was associated with at least mild incident MR (HR 1.81, 95% CI 1.11 – 2.97) and was negatively associated with at least mild incident aortic stenosis (HR 0.18, 95% CI 0.04 – 0.87) (table 3). Anti-centromere antibody trended towards significance for at least mild incident AS (HR 2.02, 95% CI 0.92 – 4.47) (table 3).

Conclusion: MR was the most common VHD found at baseline echocardiogram in this retrospective cohort of patients with SSc, and was also the most common valve abnormality to develop, typically mild in severity. Development of any severe valve disease was less common, with severe aortic stenosis having the highest IR. Follow-up time was relatively short at a mean of less than 6 years. As VHD may cause cardiac remodeling and cardiopulmonary hemodynamic changes, additional studies examining impact of VHD on cardiopulmonary outcomes in SSc and appropriate management strategies in this population are warranted.


Table 1ACR


Table 2ACR


Table 3ACR3


Disclosure: M. Elnagar, None; Y. Radwan, None; M. Elwazir, None; R. Kurmann, None; R. Mankad, None; T. Osborn, None; A. Makol, None; L. Griffing, None; C. Crowson, None; A. Hinze, None.

To cite this abstract in AMA style:

Elnagar M, Radwan Y, Elwazir M, Kurmann R, Mankad R, Osborn T, Makol A, Griffing L, Crowson C, Hinze A. Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/incidence-rate-and-prevalence-of-valvular-heart-disease-in-systemic-sclerosis-a-retrospective-cohort-study-from-a-single-institution/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-rate-and-prevalence-of-valvular-heart-disease-in-systemic-sclerosis-a-retrospective-cohort-study-from-a-single-institution/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology